Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;30(4):395-423.
doi: 10.1016/j.thorsurg.2020.08.001. Epub 2020 Sep 14.

Mesothelioma Biomarkers: Discovery in Search of Validation

Harvey I Pass  1 , Marjan Alimi  2 , Michele Carbone  3 , Haining Yang  3 , Chandra M Goparaju  2
Affiliations
Review

Mesothelioma Biomarkers: Discovery in Search of Validation

Harvey I Pass et al. Thorac Surg Clin. 2020 Nov.

Abstract

Malignant pleural mesothelioma (MPM) is an asbestos-related neoplasm that can only be treated successfully when correctly diagnosed and treated early. The asbestos-exposed population is a high-risk group that could benefit from sensitive and specific blood- or tissue-based biomarkers. We review recent work with biomarker development in MPM and literature of the last 20 years on the most promising blood- and tissue-based biomarkers. Proteomic, genomic, and epigenomic platforms are covered. SMRP is the only validated blood-based biomarker with diagnostic, monitoring and prognostic value. To strengthen development and testing of MPM biomarkers, cohorts for validation must be established by enlisting worldwide collaborations.

Keywords: Asbestos; Biomarkers; Diagnosis; Mesothelioma; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure H.I. Pass reports funding from the National Cancer Institute, the Department of Defense, the Centers for Disease Control and Prevention, Genentech, and Belluck and Fox. Financial support for this article was only for H.I. Pass (5U01CA214195-04The EDRN Mesothelioma Biomarker Discovery Laboratory). M. Carbone and H. Yang report grants from the NIH, National Cancer Institute, the US Department of Defense, and the UH Foundation through donations to support research on “Pathogenesis of Malignant Mesothelioma” from Honeywell International Inc., Riviera United-4-a Cure, and the Maurice and Joanna Sullivan Family Foundation. M. Carbone has a patent issued for BAP1. M. Carbone and H. Yang have a patent issued for “Using Anti-HMGB1 Monoclonal Antibody or other HMGB1 Antibodies as a Novel Mesothelioma Therapeutic Strategy,” and a patent issued for “HMGB1 As a Biomarker for Asbestos Exposure and Mesothelioma Early Detection.” Michele Carbone is a board-certified pathologist who provides consultation for mesothelioma expertise and diagnosis. The remaining authors report no disclosures.

MeSH terms

LinkOut - more resources